10. (new) The method of claim 8 wherein the human α-interferon is obtained from a lymphoblastoid cell culture.

11. (new) The method of claim 7 wherein the human α-interferon is obtained from a lymphocyte cells.

12. (new) The method of claim 8 wherein the human α-interferon is obtained from a lymphocyte cells.

13. (new) The method of claim 7 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

14. (new) The method of claim 8 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

15. (new) The method of claim 9 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

16. (new) The method of claim 10 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

17. (new) The method of claim 11 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

18. (new) The method of claim 12 wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

19. (new) A liquid pharmaceutical composition for oral administration comprising natural human α-interferon at a concentration between 100 IU/ml and 500 IU/ml, wherein the α-interferon is obtained from cells of the group consisting of lymphoblastoid cell cultured cells and lymphocyte cells.

Respectfully submitted,

Dated: September 15, 2000

Ronald B. Hildreth
Patent Office Reg. No. 19,498

Lisa B. Kole
Patent Office Reg. No. 35,225

Attorneys for Applicants
(212) 408-2500

Enclosures